🔎 Trials Near Me

Akèy › Limfòm selil B › Illinois › Chicago

Etid klinik pou Limfòm selil B nan Chicago, IL

12 etid pou Limfòm selil B ap chèche patisipan nan sit nan ak bò kote Chicago (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Ap rekriteFaz 3
  • Rush University Medical Center, Chicago
  • University of Chicago Medical Center, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06742996

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Ap rekriteFaz 1
  • The University of Chicago Medical Center (UCMC), Chicago
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

Ap rekriteFaz 2
  • Research Site, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06526793

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Ap rekriteFaz 1
  • University of Chicago Comprehensive Cancer Center, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT05272384

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Ap rekriteFaz 1/2
  • University of Chicago Medical Center, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04104776

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Ap rekriteFaz 1
  • The David and Etta Jonas Center for Cellular Therapy, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06528301

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Ap rekriteFaz 3
  • Northwestern, Chicago
  • University of Chicago, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

Ap rekriteFaz 2
  • Robert H Lurie Cancer Center, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489

Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

Ap rekriteFaz 2
  • Northwestern University, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Jul 8, 2026 · NCT06723457

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

Ap rekriteFaz 1/2
  • University of Illinois at Chicago Cancer Center, Chicago
Laj 12 a 95 · Tout sèks · Mizajou Apr 15, 2026 · NCT04329728

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

Ap rekriteFaz 1/2
  • The University of Chicago Medical Center (UCMC), Chicago
Laj 18 a 80 · Tout sèks · Mizajou Aug 24, 2025 · NCT05607420

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Ap rekriteFaz 1
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770

Etid Limfòm selil B nan lòt vil

Lòt etid nan Chicago

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.